Financial Overview of Inventiva's Q3 2025
Inventiva, a clinical-stage biopharmaceutical company, recently unveiled its financial performance for the third quarter of 2025. The focus of this report lies in cash reserves, revenue generation, and future business plans.
Cash and Cash Equivalents
As of September 30, 2025, Inventiva reported €97.6 million in cash and cash equivalents, illustrating a slight increase from €96.6 million at the end of 2024. Such liquidity positions the company well for future operations.
Operating Activities and R&D Expenses
For the first nine months of 2025, Inventiva experienced net cash used in operating activities totaling (€76.3) million. While this figure reflects an increase compared to (€63.7) million during the same period in 2024, it underscores the growing operational expenditures. Research and development expenses witnessed a modest decrease to (€64.6) million, representing an 11% reduction, indicating effective management of R&D investments.
Investment Activities
In terms of investment, the company faced a net cash outflow of (€25.0) million in the first three quarters of 2025, a significant shift from the €8.9 million generated during the same timeframe in 2024. This change is primarily attributed to movements in short-term deposits. Despite the increase in investment spending, the company remains optimistic due to its strong cash position.
Financing Activities Outcome
On a positive note, Inventiva generated €103.4 million from financing activities, an increase from €41.9 million in the previous year. This financing success primarily stemmed from receiving gross proceeds of €115.6 million in May 2025 through the second tranche of a structured financing arrangement. Such funding is crucial for supporting ongoing research and operational activities.
Revenue Generation
Revenues for the first nine months of 2025 amounted to €4.5 million, a significant leap from no revenues during the same period in 2024. This increase is credited predominantly to a $10 million milestone payment from Chia Tai Tianqing Pharmaceutical Group, along with revenue generated under licensing agreements.
Future Financial Outlook
Looking ahead, Inventiva's financial strategy appears robust. The completion of a public offering in November 2025 is expected to yield gross proceeds of approximately €149 million. This influx of capital is anticipated to sustain operational needs through at least the end of the first quarter of 2027.
Key Upcoming Milestones
Inventiva plans to release the topline results of its pivotal Phase 3 clinical trial, NATiV3, in the latter half of 2026. This trial holds significant importance for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients, and its results will likely influence the company's strategic direction.
Engagement with Shareholders and Investors
A Combined General Meeting of Shareholders is scheduled for November 27, 2025. This meeting will present an opportunity for dialogue regarding company performance and future directions. Additionally, Inventiva is set to participate in various investor conferences, including the Euronext Tech Leaders Forum and the Piper Sandler Healthcare Conference, which serve as platforms for showcasing the company’s advancements.
Summary of Inventiva
Inventiva primarily focuses on developing oral therapies for MASH patients. With the ongoing evaluation of lanifibranor in clinical trials, the company remains committed to innovation in the biopharmaceutical sector. Listed on Euronext Paris and Nasdaq (tickers: IVA, IVEVF), Inventiva continues to position itself as a leader in its domain.
Frequently Asked Questions
What is the financial position of Inventiva as of Q3 2025?
Inventiva reported €97.6 million in cash and cash equivalents, ensuring strong liquidity for future operations.
What were Inventiva's revenues for the first nine months of 2025?
Revenues amounted to €4.5 million attributed mostly to milestone payments and licensing agreements.
How has Inventiva's operational spending changed?
Net cash used in operating activities increased to (€76.3) million, reflecting higher operational costs compared to the previous year.
What upcoming milestones does Inventiva have?
Inventiva anticipates releasing topline results for the NATiV3 trial in the second half of 2026.
How is Inventiva planning for future financing?
The company recently completed a public offering generating approximately €149 million, facilitating operational financing until mid-2027.
